Key Highlights

  • Research and development expense rose 377% to USD 3,892,387.
  • Net loss was USD 7,224,070, or USD 7.42 per share.
  • Product Revenue was USD 13,942 in the quarter.
  • Cash fell to USD 300,623 from USD 3,789,342.

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) reported a third-quarter 2026 net loss of USD 7,224,070 versus USD 2,288,034, or USD 7.42 per share versus USD 5.04. The Earnings data lists an estimated loss of USD 3.75 per share and estimated revenue of USD 602 thousand, while the filing reports product revenue of USD 13,942.

Research and development expense was USD 3,892,387 versus USD 816,697, an increase of about 377%, and general and administrative expense was USD 1,912,927 versus USD 1,480,356. Total operating expenses were USD 5,805,314 versus USD 2,297,053, and the operating loss was USD 5,795,706.

Interest income was USD 7,223 versus USD 10,212, and the Cost of Goods Sold on the revenue was USD 4,334, leaving Gross Profit of USD 9,608.

Other Items and Nine-Month Results

Other expenses totaled USD 1,428,364, including a USD 1,252,798 loss on the change in Fair Value of convertible notes and a USD 114,691 loss on the change in fair value of license consideration payable. Interest expense was USD 68,098.

For nine months, the net loss was USD 11,560,425 versus USD 6,069,866, or USD 17.28 per share versus USD 13.61. Product revenue was USD 56,839 and gross profit was USD 44,962, with no revenue in the prior-year period. Research and Development was USD 4,903,789 and general and administrative expense was USD 5,642,824.

Accrued compensation was USD 528,616 versus USD 1,397,357, prepaid contracts were USD 766,667 and inventory was USD 130,957. Research and development expense for nine months was up about 140%, an increase of USD 2,860,899.

Balance Sheet and Financing

Cash was USD 300,623 at September 30 versus USD 3,789,342 at year-end, and total Assets were USD 1,623,134. Total liabilities fell to USD 2,785,136 from USD 7,395,882, with convertible notes payable at fair value dropping to USD 225,688 from USD 5,298,068, while a license consideration payable of USD 1,058,546 appeared. The stockholders' Deficit was USD 1,162,002.

During the quarter the company issued 132,867 shares under a license agreement, issued 199,861 shares to settle notes and interest, sold shares under an Equity line for USD 87,055 and completed a registered direct offering of 307,692 shares with net proceeds of about USD 1.86 million.

Weighted average shares were 973,633 for the quarter versus 453,865, and 1,318,521 common shares were outstanding versus 459,286 at year-end, so the per-share loss reflects both a much larger loss and a larger weighted share count than a year earlier. Additional paid-in Capital was USD 45,065,317 and the accumulated deficit was USD 46,227,451.

Business Profile and Items to Follow

The company is a clinical-stage pharmaceutical firm in Palm Beach Gardens, Florida, built around JOTROL, a patented micellar resveratrol formulation with an ongoing Phase IIa study in Parkinson's disease. It is also expanding into a consumer longevity line called Nugevia, which supports mental clarity, skin health and mitochondrial function.

The filing describes the company as a "clinical stage research and development pharmaceutical company". Items to follow include cash use against the USD 300,623 balance, further financing, the Parkinson's study and Nugevia sales.